“We are targeting the first of a series of potential approvals in 2028.”

In context

“placebo group. We're encouraged by these results as they serve as an important proof of concept for the delivery of our fourfold equivalent monthly dose that maintains competitive tolerability, particularly given the study protocol did not permit down titration. The totality of tolerability data support our plans to evaluate a higher monthly dose of 9.6 milligrams in phase three, which is the monthly equivalent to the 2.4 milligram weekly dose currently being studied in the ongoing VESPA four trial. Today's encouraging results bolster our expansive obesity program. This year, we plan to advance 20 plus obesity trials, including 10 phase three studies of 3944 that span chronic weight management, obesity-associated comorbidities, and opportunities to increase patient optionality and access. We are targeting the first of a series of potential approvals in 2028. Looking to our early-stage programs, we are enthusiastic about phase two studies with our ultra-long-acting amylin analog, which we believe has the potential for class-leading efficacy and combinability with 3944 in a monthly dosing format. We previously reported positive early data from the single ascending dose combination study, which showed well-tolerated starting doses and additive weight loss. We plan to show updated combination data later this year. We continue to advance our potentially first-in-class oral Gipper antagonist that is in phase two, and additional phase one studies of agents with diverse modalities and mechanisms. These include an injectable ultra-long-acting GiPA agonist, a potential quarterly dose injectable GLP-1 receptor agonist, and oral candidates. To summarize,”